Canakinumab treatment is associated with improved hemoglobin levels in patients with concurrent baseline anemia and CH mutations. Hemoglobin response to treatment in patients with baseline anemia (A) stratified according to CH mutations, patients with CH mutations (B) stratified according to anemia, and all patients (C) as per the CH-risk score, and adjusted for baseline hemoglobin, hsCRP, and age. (A) Hemoglobin response to canakinumab (blue) and placebo (red) in patients with concurrent baseline anemia and indicated mutations. (B) Hemoglobin response to canakinumab in patients with baseline anemia (blue) or without baseline anemia (purple) among patients with CH mutations. (C) Changes of hemoglobin levels from baseline in response to canakinumab or placebo in patients with no CH, low-risk, intermediate-risk, and high-risk score of CH. BL, baseline; Hb, hemoglobin; LS, least squares; M, month; N/A, not applicable; P, P value of the treatment by quadratic-time effect.